Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover - 2'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- 3Genetic study identifies earliest-known dog, dating to 15,800 years ago
- 4Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- 5No injuries after blast at pro-Israel centre in the Netherlands
- Vacation destinations in America
- The most exciting exoplanet discoveries of 2025
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- Figure out How to Score Huge with Open Record Rewards
- The Response Uncovered: Disentangling the Secrets of the Universe
- Audits of 6 European Busssiness Class Flights
- Top 15 Web-based Entertainment Stages for Individual Marking
- We tasted one of the 10,000 Hershey's Dubai chocolate bars being resold on eBay. Is it worth the hype?
- Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this?
